Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
The newly launched Genomic Health Insights (GHI) program to make sequencing accessible to all
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
This product will be launched through Granules Consumer Health (GCH) division
Approval to dramatically change CAR-T therapies landscape
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Advances clinical research capabilities with leading regulatory grade registries platform
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
Subscribe To Our Newsletter & Stay Updated
